Mr. John Ansell MBA
Director, John Ansell Consultancy
Member of the Healthcare Council
Council Member Biography
John Ansell has been the Director of John Ansell Consultancy, a pharmaceutical consulting firm in Thame, UK, since 1990. Mr. Ansell has advised over 130 pharma, biotech and companies providing pharmaceutical services. He focuses on international marketing and business development projects, reflecting his 20 years experience in the pharma industry with Organon, Schering AG, Fisons, Solvay and Glaxo. Mr. Ansell has acted as Chairman at over 30 pharma conferences, is a frequent speaker on marketing, deals and R&D strategy, and has authored over 40 articles. He is qualified in Biochemistry (BSc Hons, Liverpool University) and Business Studies (MA, Sheffield University). Since 2007 he has been an Honorary Consultant to the University of Manchester University School of Pharmacy and Pharmaceutical Sciences. Mr. Ansell is the author of Falconbury's "Understanding the Pharmaceutical Industry" distance learning course and runs in-house courses on this and other pharmaceutical topics. (This is me - Update Profile)
Employment History
- 1990 - Unspecified
- Director, John Ansell Consultancy
GLG NewsSM Analyses by John Ansell
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
It’s official: the rise of blockbusters is at an end
August 18, 2011
Top 200 medicine highlights | pharmalive.com
The much heralded decline in the number of blockbusters has now come to pass. There were 118 products in 2010: down from 126 in 2009. Patent expiries account for most of this decline. But of particular concern is the number of new blockbusters – only 4 in 2010. It took longer than many expected for a lack of new products to undermine blockbuster numbers. Likewise, I expect it to take six years at least to reverse the current downward trend, even with a quick upturn in new product productivity.
-
Almirall deal with Nycomed says more about Daxas prospects than meets the eye
May 6, 2011
Nycomed and Almirall announce commercialization agreement for roflumilast in Spain | www.nycomed.com
Almirall and Nycomed have announced a one-off deal giving the former co-marketing rights to its new COPD product roflumilast . This strongly suggests that the product's sales progress since last autumn across Europe has been good - sufficient for Almirall to think it worth belatedly entering the fray in Spain. Daxas should soon have the credibility to attract partners - including Almirall - for developing fixed combinations, a potentially much bigger prize.
-
Actelion undermined by loss of its crown jewel project
January 28, 2011
GSK and Actelion discontinue clinical development of almorexant | www.gsk.com
Actelion and GSK have announced that clinical development of their Phase III compound for insomnia, almorexant, has been discontinued. This has severe implications for the future of Actelion in particular.
-
Merck shifts away from CNS whilst bolstering respiratory
October 26, 2010
Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST | www.merck.com
A shift of emphasis by Merck & Co away from the CNS area could also indicate a further licensing opportunity. This contrasts with further recent concentration by the company on the respiratory area.
-
Pfizer's licensing judgment in question
July 7, 2010
Two recently approved new products, Saphris/Sycrest (asenapine) and Daxas (roflumilast), were both once in-licensed projects which belonged half a dozen years ago to Pfizer's R&D pipeline. Pfizer not long afterwards returned rights to both compounds to the licensor companies. Its US rival Merck & Co now holds rights to both of these new products. We explore how this could have come to pass.
GLG Study Groups with John Ansell(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 890 |
| Generic Pharmaceuticals Economic Experts (Germany) | 58 |
GLG Live Meetings with John Ansell(?)
John Ansell has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.